Nwam LLC Buys 193 Shares of Zoetis Inc. (NYSE:ZTS)

Nwam LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 4.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,908 shares of the company’s stock after buying an additional 193 shares during the period. Nwam LLC’s holdings in Zoetis were worth $959,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. GM Advisory Group LLC increased its stake in Zoetis by 35.7% in the third quarter. GM Advisory Group LLC now owns 1,899 shares of the company’s stock valued at $371,000 after acquiring an additional 500 shares during the last quarter. Allen Capital Group LLC increased its position in shares of Zoetis by 23.4% during the 3rd quarter. Allen Capital Group LLC now owns 2,466 shares of the company’s stock valued at $482,000 after purchasing an additional 467 shares during the last quarter. Biltmore Family Office LLC raised its holdings in shares of Zoetis by 5.0% during the 3rd quarter. Biltmore Family Office LLC now owns 1,771 shares of the company’s stock valued at $346,000 after buying an additional 85 shares in the last quarter. First County Bank CT bought a new stake in Zoetis in the 3rd quarter worth approximately $318,000. Finally, Darden Wealth Group Inc purchased a new stake in Zoetis in the third quarter worth approximately $219,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.1 %

NYSE ZTS opened at $176.96 on Friday. The stock has a market cap of $79.84 billion, a P/E ratio of 33.26, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a 50 day simple moving average of $185.62 and a two-hundred day simple moving average of $180.61. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.36 earnings per share. On average, analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ZTS. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus boosted their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.